摘要
目的研究低剂量阿帕替尼联合卡培他滨在晚期乳腺癌中的治疗效果。方法分析该院肿瘤外科和肿瘤内科自2015年3月至2018年1月收治的经多线治疗失败的晚期乳腺癌患者40例,分为观察组和对照组,观察组采用低剂量阿帕替尼联合卡培他滨治疗,对照组采用卡培他滨治疗。观察两组的病灶缓解情况、无进展生存期(PFS)及不良反应。结果观察组病灶缓解率明显高于对照组(P<0.05),观察组患者PFS明显长于对照组(P<0.05),其中观察组中位PFS为4.69个月,95%CI:3.44~5.76。对照组中位PFS为2.11个月,95%CI:1.29~2.93;两组不良反应差异无统计学意义(P>0.05)。结论低剂量阿帕替尼联合卡培他滨治疗晚期多线治疗失败乳腺癌是安全有效的。
Objective To study the therapeutic effect of low-dose apatinib combined with capecitabine in advanced breast cancer.Methods A total of 40 patients with advanced breast cancer with the failed treatment of multi-line therapy from March 2015 to January 2018 were enrolled in the observation group and the control group.The observation group was treated with low-dose apatinib combined with capecitabine,the control group was treated with capecitabine.The lesion remission,progression-free survival(PFS),and adverse events were observed in the two groups.Results The remission rate of the observation group was significantly higher than that of the control group(P<0.05).The PFS of the observation group was significantly longer than that of the control group(P<0.05).The median PFS of the observation group was 4.69 months,95%CI:3.44-5.76.The median PFS of the control group was 2.11 months,95%CI:1.29-2.93.The adverse reaction of the observation group increased slightly when compared with the control group,but the difference was not statistically significant(P>0.05).The adverse reaction was no significant difference betweent the two groups(P>0.05).Conclusion Low-dose of apatinib combined with capecitabine is safe and effective in treatment of advanced breast cancer with failed of multi-line therapy.
作者
单宏杰
肖迎利
李红
马骖
SHAN Hongjie;XIAO Yingli;LI Hong;MA Wei(Department of Oncology Surgery,Suzhou Hospital Affiliated to Anhui Medical University,Suzhou,Anhui 230032,China;Department of Medicine Oncology,Suzhou Hospital Affiliated to Anhui Medical University,Suzhou,Anhui 230032,China)
出处
《重庆医学》
CAS
2019年第16期2800-2803,共4页
Chongqing medicine
